NCT05047094View on ClinicalTrials.gov

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Head and Neck Squamous Cell CarcinomaSkin CancerMetastatic Head-and-neck Squamous-cell Carcinoma
Interventions
DEVICE

Diffusing Alpha Radiation Emitters Therapy (DaRT)

An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

DRUG

Pembrolizumab

200 mg administered as an intravenous infusion over 30 minutes every 3 weeks

Trial Locations (3)

91120

RECRUITING

Sharett institute, Hadassah University Hospital - Ein-Kerem, Jerusalem

Unknown

RECRUITING

Sheba Medical Center, Ramat Gan

NOT_YET_RECRUITING

Tel-Aviv Medical Center, Tel Aviv

Sponsors
All Listed Sponsors
lead

Alpha Tau Medical LTD.

INDUSTRY

NCT05047094 - A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | Biotech Hunter | Biotech Hunter